Clinical Trials /

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

NCT02252146

Description:

Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 30% of the patients with the activated B-cell (ABC) type of Diffuse Large B Cell Lymphoma (DLBCL). MYD88 is an initial adapter linker protein in the signaling pathway of the Toll Like Receptors (TLRs), including the endosomal TLRs 7, 8, and 9, for which the ligands are nucleic acids. IMO-8400 is an oligonucleotide specifically designed to inhibit ligand activation of TLRs 7,8, and 9. Recent studies indicate that in the presence of L265P mutation ligand activation of those TLRs results in markedly increased signaling with subsequent increased cell activation, cell survival, and cell proliferation. The scientific rationale for assessing the use of IMO-8400 to treat patients with DLBCL and the L265P mutation is based on laboratory observations that IMO-8400 inhibits ligand-based activation of cells with the mutation and decreases the survival and proliferation of the cell populations responsible for the propagation of the disease.

Related Conditions:
  • Diffuse Large B-Cell Lymphoma
Recruiting Status:

Completed

Phase:

Phase 1/Phase 2

URL:

https://clinicaltrials.gov/show/NCT02252146

Trial Eligibility

Document

Title

  • Brief Title: Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
  • Official Title: Phase I/II Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Presence of the MyD88 L265P Mutation

Clinical Trial IDs

  • ORG STUDY ID: 8400-402
  • NCT ID: NCT02252146

Conditions

  • Diffuse Large B Cell Lymphoma

Interventions

DrugSynonymsArms
IMO-8400IMO-8400

Purpose

Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 30% of the patients with the activated B-cell (ABC) type of Diffuse Large B Cell Lymphoma (DLBCL). MYD88 is an initial adapter linker protein in the signaling pathway of the Toll Like Receptors (TLRs), including the endosomal TLRs 7, 8, and 9, for which the ligands are nucleic acids. IMO-8400 is an oligonucleotide specifically designed to inhibit ligand activation of TLRs 7,8, and 9. Recent studies indicate that in the presence of L265P mutation ligand activation of those TLRs results in markedly increased signaling with subsequent increased cell activation, cell survival, and cell proliferation. The scientific rationale for assessing the use of IMO-8400 to treat patients with DLBCL and the L265P mutation is based on laboratory observations that IMO-8400 inhibits ligand-based activation of cells with the mutation and decreases the survival and proliferation of the cell populations responsible for the propagation of the disease.

Detailed Description

      Eligible subjects will be enrolled and assigned to one of five dose cohorts. Treatment will
      be administered by subcutaneous injection until progression or intolerable toxicity.

Trial Arms

NameTypeDescriptionInterventions
IMO-8400ExperimentalIMO-8400 0.3 mg/kg twice weekly, 0.6 mg/kg twice weekly, or 1.2 mg/kg twice weekly
  • IMO-8400

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have a diagnosis of Diffuse Large B Cell Lymphoma (DLBCL) of non-GCB
             subtype, established according to the World Health Organization (WHO) criteria that
             has been tested for the MyD88 L265P mutation.

          -  In addition to the above, key inclusion and exclusion criteria are listed below.

               1. Be at least 18 years of age

               2. Agree to use contraception

        Exclusion Criteria:

          1. Is nursing or pregnant

          2. DLBCL of GCB subtype

          3. Has BMI > 34.9 kg/m2

          4. Has a positive test for human immunodeficiency virus (HIV-1 or -2) hepatitis C virus
             (HCV) or hepatitis B surface antigen (HBsAg)

          5. Receiving chronic systemic corticosteroid therapy > 20 mg of prednisone daily

          6. Being treated with other anti-cancer therapies (approved or investigational)

          7. Has an active infection requiring systemic antibiotics

          8. Has had surgery requiring general anesthesia within 4 weeks of starting the study

          9. Has heart failure of Class III or IV
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Number of Participants With Adverse Events, Injection Site Reactions, and Concomitant Medications
Time Frame:Up to 2 years from first patient visit
Safety Issue:
Description:Frequency of adverse events, injection site reactions, and concomitant medications observed

Details

Phase:Phase 1/Phase 2
Primary Purpose:Interventional
Overall Status:Completed
Lead Sponsor:Idera Pharmaceuticals, Inc.

Trial Keywords

  • DLBCL
  • MYD88 L265P
  • Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Idera
  • IMO 8400

Last Updated

December 12, 2017